Original research:

    1. Wang EC, Min Y, Palm RC, Fiordalisi J, Wagner KT, Hyder N, Tian X, Moore D, Caster J, Cox AD, Wang AZ. Nanoparticle formulations of histone deacetylase inhibitors for effective chemoradiotherapy in solid tumors. Biomaterials. 2015, May;51:208-15. doi: 10.1016/j.biomaterials.2015.02.015. Epub 2015 Feb 19.
    2. Caster JM, Sethi M, Kowalczyk S, Wang E, Tian X, Hyder SN, Wagner KT, Zhang YA, Kapadia C, Au KM and Wang AZ. Nanoparticle delivery of chemosensitizers to improve chemotherapy efficacy without incurring additional toxicity. Nanoscale, 2015, 7, 2805-2811
    3. Byrne JD, Jajja MR, O’Neill AT, Bickford LR, Keeler AW, Hyder N, Wagner K, Deal A, Little RE, Moffitt RE, Stack C, Nelson M, Brooks C, Lee W, Luft C, Napier ME, Darr D, Anders RC, Stack R, Tepper JE, Wang AZ, Zamboni WC, Yeh JJ, DeSimone JM. Local Iontophoretic Administration of Cytotoxic Therapies to Solid Tumors. Science Translational Medicine. 2015 Feb 4;7(273):273ra14.
    4. Sethi M, Sukumar R, Karve S, Werner ME, Wang EC, Moore DT, Kowalczyk SR, Zhang L, Wang AZ. Effect of Drug Release Kinetics on Nanoparticle Therapeutic Efficacy and Toxicity. Nanoscale, 2014, 6 (4), 2321 – 2327
    5. Della Rocca J, Werner ME, Kramer SA, Huxford-Phillips RC, Sukumar R, Cummings ND, Vivero-Escoto JL, Wang AZ*, Lin W*. Polysilsesquioxane Nanoparticles for Triggered Release of Cisplatin and Effective Cancer Chemoradiotherapy. Nanomedicine: Nanotechnology Biology and Medicine, 2014 Jul 17. pii: S1549-9634(14)00391-8. . *Corresponding authors. 2014, 4 pages.
    6. Chen RC, Hendrix LH, Carpenter WR, Bainbridge J, Wang AZ, Nielsen ME, Godley PA. Receipt of guideline-concordant treatment in elderly prostate cancer patients. Int J Radiat Oncol Biol Phys., 2014 Feb: 88 (2):332-338.
    7. Xu Z, Chen RC, Wang AZ, Kress A, Foskey M, Qin A, Cullip T, Tracton G, Chang S, Tepper J, Yan D, and Chaney E. Comparison of User-Directed and Automatic Mapping of the Planned Isocenter to Treatment Space for Prostate IGRT," International Journal of Biomedical Imaging, vol. 2013, Article ID 892152, 12 pages, 2013.
    8. Chu KS, Schorzman AN, Finniss MC, Bowerman CJ, Peng L, Luft JC, Madden AJ, Wang AZ, Zamboni WC, Desimone JM. Nanoparticle drug loading as a design parameter to improve docetaxel pharmacokinetics and efficacy. Biomaterials, 2013 Nov;34(33):8424-9.
    9. Wang EC, Sinnott R, Werner ME, Sethi M, Whitehurst AW, Wang AZ. Differential Cell Responses to Nanoparticle Docetaxel and Small Molecule Docetaxel at a Sub-Therapeutic Dose Range. Nanomedicine: Nanotechnology Biology and Medicine. 2013. Aug 3. pii: S1549-9634(13)00353-5.
    10. Gallagher SASmith ABMatthews JEPotter CWWoods MERaynor MWallen EMKimryn Rathmell WWhang YEKim WYGodley PAChen RCWang A, You CBarocas DAPruthi RSNielsen MEMilowsky MI. Roadmap for the development of the University of North Carolina at Chapel Hill Genitourinary OncoLogy Database-UNC GOLD. Urol Oncol. 2013 Feb 19 pii:S1078-1439(12)
    11. Werner ME, Cummings ND, Sukumar R, Sethi M, Wang EC, Moore DT, Dees EC, Wang AZ. Preclinical evaluation of Genexol-PM, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer. Int J Radiat Oncol Biol Phys,  2013 Jul 1;86(3):463-8.
    12. Stokes WA, Hendrix LH, Royce TJ, Allen IM, Godley PA, Wang AZ, Chen RC. Racial differences in time from prostate cancer diagnosis to treatment initiation, a population-based study. Cancer, 2013 Jul 1;119(13):2486-93.
    13. Karve S, Werner ME, Sukumar R, Cummings ND, Copp JA, Wang EC, Li C, Chen RC, Pacold ME, Wang AZ. Revival of the Abandoned Therapeutic Wortmannin by Nanoparticle Drug Delivery. Proceedings of the National of Academy of Sciences, 2012 May 22;109(21):8230-5.
    14. Chen RC, Rosenman JG, Hoffman LG, Chiu WK, Wang AZ, Pruthi RS, Wallen EM, Crane JM, Kim WY, Rathmell WK, Godley PA, Whang YE. Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer. British Journal of Urology.  2012 Sep 27.
    15. Werner ME, Foote MB, Wang AZ. Chemoradiotherapy of Human Tumors: Novel Approaches from Nanomedicine. Current Pharmaceutical Design, 2012;18(19):2830-7.
    16. Di Pasqua AJ, Huckle JE, Kim JK, Chung Y, Wang AZ, Jay M, Lu X. Preparation of Neutron Activatable Holmium Nanoparticles for the Treatment of Ovarian Cancer Metastases. Small, Apr 10;8(7):997-1000.
    17. Holmes JA, Wang ZA, Hoffman KE, Hendrix LH, Rosenman JG, Carpenter WR, Godley PA, Chen RC. Is Primary Prostate Cancer Treatment Influenced by Likelihood of Extraprostatic Disease? A Patterns of Care Study Using the Surveillance Epidemiology and End Results Database. Int J Radiat Oncol Biol Phys, 2012 Jan 31.
    18. Werner ME, Karve S, Sukumar R, Cummings ND, Copp JA, Chen RC, Zhang T, Wang AZ. Folate targeted nanoparticle delivery of chemo- and radio-therapeutics for the treatment of ovarian cancer peritoneal metastasis. Biomaterials, 2011 Nov;32(33):8548-54. 
    19. Werner ME, Copp JA, Karve S, Cummings ND, Sukumar R, Napier M, Chen RC, Cox AD, Wang AZ. Folate-targeted polymeric nanoparticle formulation of docetaxel is an effective molecularly targeted radiosensitizer with efficacy dependent on the timing of radiotherapy. ACS Nano, 2011 Nov 22;5(11):8990-8.
    20. Karve S, Werner ME, Cummings ND, Sukumar R, Wang EC, Zhang YA, Wang AZ. Formulation of diblock polymeric nanoparticles through nanoprecipitation technique. J Vis Exp. 2011 Sep 20;(55)
    21. Merkel TJ, Jones SW, Herlihy KP, Kersey FR, Shields AR, Napier M, Wang AZ, Bear JE, DeSimone JM. Using Mechano-biological Mimicry to Extend Circulation Times of Red Blood Cell Replicas. Proceedings of the National Academy of Sciences, 2011 Jan 11;108(2):586-91. PMCID: PMC3021010
    22. Wang AZ, Yuet K, Zhang LF, Gu FX, Huynh-Le M, Radovic-Moreno AF, Kantoff PW, Bander NH, Langer R, Farokhzad OC. ChemRad Nanoparticles: A Novel Multifunctional Nanoparticle Platform for Targeted Delivery of Concurrent Chemoradiation. Nanomedicine, 2010 Apr; 5(3): 361-8. PMCID: PMC2901911
    23. Wang AZ, Bagalkot V, Vasilliou C, Gu F, Alexis F, Zhang LF, Shaikh M, Yuet K, Cima M, Langer R, Kantoff PW, Bander NH, Jon S, Farokhzad OC. Superparamagnetic Iron Oxide Nanoparticle-Aptamer Bioconjugates for Combined Prostate Cancer Imaging and Therapy. ChemMedChem. 2008, 3(9):1311-5.
    24. Wang AZ, Gu F, Zhang LF, Chan JM, Radovic-Moreno A, Shaikh MR, Farokhzad OC. Biofunctionalized Targeted Nanoparticles for Therapeutic Applications. Expert Opinions on Biological Therapy, 2008; 8(8):1063-70.
    25. Gu F, Zhang LF, Teply B, Mann N, Wang A, Radovic-Moreno AF, Langer R, Farokhzad OC. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block co-polymers. Proceedings of the National of Academy of Sciences, 2008, 105(7): 2586-91.
    26. Tam WF, Gu TL, Chen J, Lee BH, Bullinger L, Fröhling S, Wang A, Monti S, Golub TR, Gilliland DG. Oncogenic tyrosine kinases upregulate Id1 in leukemic cells. Blood, 2008, 112(5):1981-92.
    27. Zhang L, Chan J, Gu F, Rhee JW, Wang AZ, Radovic-Moreno A, Alexis F, Langer R, Farokhzad OC. Self-assembled lipid-polymer hybrid nanoparticles: A robust drug delivery platform. ACS Nano, 2008, 2(8); 1696-1702.

Alexis F, Basto P, Levy-Nissenbaum E, Radovic-Moreno AF, Zhang L, Pridgen E, Wang AZ, Marein SL, Westerhof K, Molnar LK, Farokhzad OC. HER-2-Targeted Nanoparticle-Affibody Bioconjugates for Cancer Therapy. ChemMedChem, 2008, 3(12): 1839-184

o             Other peer-reviewed articles:
    1. Wang AZ, Tepper JE. Nanotechnology in Radiation Oncology. J Clin Oncol. 2014 Sep 10;32(26):2879-2885. 
    2. Wang AZ, Farokhzad OC. Current Progress of Aptamer-Based Molecular Imaging. J Nucl Med. 2014 Feb 13. Epub
    3. Chapman S, Dobrovolskaia M, Farahani K, Goodwin A, Joshi A, Lee H, Meade T, Pomper M, Ptak K, Rao J, Singh R, Sridhar S, Stern S, Wang AZ, Weaver JB, Woloschak G, Yang L. Nanoparticles for cancer imaging: the good, the bad and the promise. Nanotoday, Volume 8, Issue 5, October 2013, Pages 454–460.
    4. Wang EC, Wang AZ. Nanoparticles and their applications in cell and molecular biology. Integr Biol (Camb). 2014 Jan;6(1):9-26. Review.
    5. Liu D, He C, Wang AZ, Lin W. Application of liposomal technologies for delivery of platinum analogs in oncology. Int J Nanomedicine. 2013;8:3309-19.
    6. Goldberg MSHook SSWang AZBulte JWPatri AKUckun FMCryns VLHanes JAkin DHall JBGharkholo NMumper RJ. Biotargeted nanomedicines for cancer: six tenets before you begin. Nanomedicine (Lond). 2013 Feb;8(2):299-308.
    7.  Miller SM, Wang AZ. Nanomedicine in chemoradiation. Ther Deliv. 2013 Feb;4(2):239-50.
    8. Wang AZ, Langer R, Farokhzad OC. Nanoparticle Delivery of Cancer Drugs. Annual Reviews of Medicine. 2012;63:185-98.
    9. McRee AJ, Cowherd S, Wang AZ, Goldberg RM. Chemoradiation Therapy in the Management of Gastrointestinal Malignancies. Future Oncol. 2011 Mar;7(3): 409-26.
    10. Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, Langer R, Farokhzad OC. Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol. 2008 Aug;26(8):442-9.
    11. Zhang L, Gu FX, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in Medicine: Therapeutic Applications and Developments. Clinical Pharmacology and Therapeutics, 2007; 83(5):761-9.
    12. Gu F, Karnik R, Wang A, Alexis F, Levy-Nissenbaum E, Hong S, Langer R, Farokhzad OC. Targeted Nanoparticles for Cancer Therapy.  NanoToday, 2007; Vol. 2, No. 3, pg 14-21.
  • Editorials:
  1. Tepper JE, Wang AZ. Scoring the Recurrence Score in Rectal Cancer. JNCI, 2014 106 (11): dju295
  2. Wang, AZ. Giving failed drugs a fresh chance: a new direction for nanoparticle drug delivery. Expert Rev. Med. Devices, 2012 Sep;9(5):445-7.
  3. Wang, AZ. Nanoparticle drug delivery: focusing on the therapeutic cargo. Nanomedicine, 2012 Oct;7(10):1463-5.
  4. Tepper JE, Wang AZ. Improving local control in rectal cancer: radiation sensitizers or radiation dose? Journal of Clinical Oncology, J Clin Oncol. 2010 Apr 1;28(10):1623-4.
  5. Wang, AZ. Nanoparticle Formulations of siRNA: The Next Generation of Targeted Therapy for Lymphomas and Leukemias? EBioMedicine, 1 (2014) 101–102


  • Patent applications:
  1. Wang Y, Reid LM, Yamauchi M, Cui C, Wang AZ, Werner M. Biomatrix Scaffolds. PCT/US11/42805 (07/11).
  2. Wang Z, Pacold M, Werner M, Karve S. Novel Wortmannin Nanoparticles and Uses Thereof. US PCT/US2011/ 61431689 (01/2011).
  3. Wang Z, Werner M, Chen R, Byrne J, Karve S, Desimone J. Delivery for brachytherapy and associated methods. International PCT Patent Application No.: PCT/US2010/053357 (10/2010).
  4. Wang AZ, Farokhzad OC, Zhang LF, Radovic-Moreno A, Gu F, Langer R. Drug delivery system for pharmaceuticals and radiation. International PCT Patent Application No.: PCT/US08/082655 (12/2008).


Books and Chapters:

  1. Zhang T, Wang AZ. Chapter: Definitions of Biochemical Failure, pg 807-811. Prostate Cancer: A Comprehensive Perspective.  Springer. 2013.
  2. Sheets NC, Wang AZ. Chapter: Radioisotopes and Nanomedicine, pg 47-66. Radioisotopes: Application in Bio-medical Science. InTech, 2011.
  3. Wang AZ, Gu FX, Farokhzad OC. Nanoparticles for cancer diagnosis and therapy. Chapter: Nanoparticles for Cancer Diagnosis and Therapy, pg 209-225. Safety of Nanoparticles: From manufacturing to medical applications. Springer. 2009.
  4. Wang AZ, Radovic-Moreno AF, Farokhzad OC. Chapter: Biologically Targeted Nanoparticles as Cancer Therapeutics, pg 97-118. Bio-inspired Nanotechnology and Nanomaterials. Nova Science Publishers. 2009.
  5. Kim, S.I., Swanson, T.A., Wang, AZ. Underground Clinical Vignettes USMLE Step 2: Surgery. (4th Edition). Lippincott Williams & Wilkins/Wolters Kluwer Health. 2007